Evaxion Biotech A/S – ADR (NASDAQ: EVAX) stock price fell 44% during premarket trading after raising $24 million via a discounted share subscription.
As covered in this article, the biotech company, which rose 236% during premarket trading yesterday, saw its shares fall following the discounted bookbuild.
Evaxion sold 3.43 million shares at $7.00 each, triggering today’s decline to the $7.10 price level. Oppenheimer led the bookbuild for the share offering.
Sponsored content
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
As reported in yesterday’s article, the company initially wanted to offer 5.2 million shares to raise $40 million but reduced to 3.43 million shares.
Inventors who chased Evaxion shares higher yesterday are sitting on significant losses, especially if they bought at the highs.
However, even traders who bought the company’s shares at the closing price of $12.68 are sitting on a 44% loss.
Still, this does not mean that Evaxion shares will not rally again. Only time will tell whether yesterday’s bullish investor sentiment will return.
As for the biotech company’s fundamentals, I highlighted its deal with Merck & Co. to test its cancer immunotherapy treatment EVX-01 in collaboration with Merck’s Keytruda, which could turn into a lucrative commercial agreement if successful.
The two companies are currently running a phase 2b clinical trial on patients with stages III and IV metastatic melanoma.
*This is not investment advice.
Evaxion stock price.
Source: Tradingview
Evaxion stock price was down 44.01% during premarket trading to trade at $7.10 after falling from Thursday’s closing price of $12.68.
Should you invest in Evaxion Stock?
Tech stocks offer some of the best growth potential, but time and time again, traders and investors ask us “what are the best tech stocks to buy?” You’ve probably seen shares of companies such as Amazon and Netflix achieve monumental rises in the past few years, but there are still several tech stocks with room for significant gains. Here is our analysts view on the best tech stocks to buy right now.
Simon ist Autor und Analyst für den Bereich Finanzwesen und blickt auf über sechs Jahre professionelle Erfahrung als Trader zurück. Er absolvierte einen Bachelor in Mathematik und Informatik und hat eine Leidenschaft für die Finanzmärkte. Simon handelt FX, Rohstoffe und Aktien. Er konzentriert sich auf Price Action Trading.
